Показано 0 из 0
Дата |
---|
17.05.2024 |
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.13
|
1.28
|
1.18
|
1.15
|
1.20
|
1.16
|
|
|
6 672.44
|
24.00
|
1.10
|
1.28
|
1.10
|
1.06
|
1.27
|
1.22
|
|
|
9 218.10
|
47.00
|
1.19
|
1.29
|
1.25
|
1.19
|
1.25
|
1.2099
|
|
|
1 407.09
|
21.00
|
1.16
|
1.30
|
1.25
|
1.25
|
1.32
|
1.285
|
|
|
937.38
|
15.00
|
1.20
|
1.64
|
1.23
|
1.21
|
1.28
|
1.28
|
|
|
1 300.72
|
7.00
|
1.20
|
1.48
|
1.28
|
1.20
|
1.28
|
1.20
|
|
|
2 531.33
|
7.00
|
0.75
|
1.60
|
1.36
|
1.31
|
1.36
|
1.33
|
|
|
5 311.17
|
21.00
|
1.29
|
1.56
|
1.38
|
1.32
|
1.38
|
1.32
|
|
|
381.40
|
9.00
|
0.96
|
1.24
|
1.32
|
1.25
|
1.37
|
1.32
|
|
|
3 363.58
|
25.00
|
1.26
|
1.59
|
1.28
|
1.27
|
1.36
|
1.36
|
|
|
416.14
|
7.00
|
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR.